After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

For the first time Australian researchers have identified how exposure to smoking may cause a deadly lung disease that claims ...

Cigarette smoke damages key lung defenses, weakening the body’s ability to fight infections and leading to respiratory ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Share on Pinterest PongMoji/Getty Images Spirometry is an important tool for diagnosing and determining treatment for chronic obstructive pulmonary disease (COPD). This breathing test can detect ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Following almost a decade of research, the Monash-led team hopes the discovery can eventually lead to an effective treatment for COPD. Researchers say COPD is mainly caused by smoking, but ...

In their study, the researchers looked at the effects of cigarette smoke on Mucosal-Associated Invariant T (MAIT) cells, a ...

Check out our weekly list of new fundraisers from Lend A Hand Up, a nonprofit crowdfunding site supporting families in Cass, ...